Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies

Diabetes mellitus (DM) and cardiovascular complications are two unmet medical emergencies that can occur together. The rising incidence of heart failure in diabetic populations, in addition to apparent coronary heart disease, ischemia, and hypertension-related complications, has created a more challenging situation. Diabetes, as a predominant cardio-renal metabolic syndrome, is related to severe vascular risk factors, and it underlies various complex pathophysiological pathways at the metabolic and molecular level that progress and converge toward the development of diabetic cardiomyopathy (DCM). DCM involves several downstream cascades that cause structural and functional alterations of the diabetic heart, such as diastolic dysfunction progressing into systolic dysfunction, cardiomyocyte hypertrophy, myocardial fibrosis, and subsequent heart failure over time. The effects of glucagon-like peptide-1 (GLP-1) analogues and sodium-glucose cotransporter-2 (SGLT-2) inhibitors on cardiovascular (CV) outcomes in diabetes have shown promising results, including improved contractile bioenergetics and significant cardiovascular benefits. The purpose of this article is to highlight the various pathophysiological, metabolic, and molecular pathways that contribute to the development of DCM and its significant effects on cardiac morphology and functioning. Additionally, this article will discuss the potential therapies that may be available in the future.

[1]  K. Naka,et al.  The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. , 2023, Journal of diabetes and its complications.

[2]  M. Maleki,et al.  Cognitive benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu. , 2023, Current medicinal chemistry.

[3]  A. Sahebkar,et al.  Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update , 2023, Biomedicines.

[4]  S. Patil,et al.  Suppression of Tumorigenicity 2 Pro-Inflammatory Biomarker Linking Diabetes Mellitus and Periodontitis: A Pilot Study , 2022, Medical science monitor : international medical journal of experimental and clinical research.

[5]  D. D’Alessio,et al.  Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction , 2022, Cardiovascular Diabetology.

[6]  Yang Zhang,et al.  Plin5, a New Target in Diabetic Cardiomyopathy , 2022, Oxidative medicine and cellular longevity.

[7]  Yue Cheng,et al.  Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy , 2022, Oxidative medicine and cellular longevity.

[8]  B. Geest,et al.  Role of Oxidative Stress in Diabetic Cardiomyopathy , 2022, Antioxidants.

[9]  A. Cudnoch-Jędrzejewska,et al.  Remodeling and Fibrosis of the Cardiac Muscle in the Course of Obesity—Pathogenesis and Involvement of the Extracellular Matrix , 2022, International journal of molecular sciences.

[10]  P. Light,et al.  Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. , 2022, Journal of molecular and cellular cardiology.

[11]  C. Maack,et al.  Mitochondria as Therapeutic Targets in Heart Failure , 2022, Current Heart Failure Reports.

[12]  M. Maiorino,et al.  Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues , 2022, Biomolecules.

[13]  Ramakrishnan Veerabathiran,et al.  Genetic predisposition study of heart failure and its association with cardiomyopathy , 2022, The Egyptian Heart Journal.

[14]  F. Romeo,et al.  Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants , 2022, Heart Failure Reviews.

[15]  K. Kitamura,et al.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases , 2022, Hypertension Research.

[16]  P. Winocour,et al.  Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021 , 2022, BMC Nephrology.

[17]  R. Kaur,et al.  Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-α expressions affecting oxidative/nitrosative stress and inflammation , 2022, Human & experimental toxicology.

[18]  Nor Azian Abdul Murad,et al.  Coronary Heart Disease in Type 2 Diabetes Mellitus: Genetic Factors and Their Mechanisms, Gene-Gene, and Gene-Environment Interactions in the Asian Populations , 2022, International journal of environmental research and public health.

[19]  L. Cai,et al.  Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways , 2021, Acta pharmaceutica Sinica. B.

[20]  Xin-Fu Zhou,et al.  Novel oral edaravone attenuates diastolic dysfunction of diabetic cardiomyopathy by activating the Nrf2 signaling pathway. , 2021, European journal of pharmacology.

[21]  Jin Han,et al.  Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  Q. Ning,et al.  IUGR with catch-up growth programs impaired insulin sensitivity through LRP6/IRS-1 in male rats , 2021, Endocrine connections.

[23]  Yuehua Jiang,et al.  Quercetin Attenuates Cardiac Hypertrophy by Inhibiting Mitochondrial Dysfunction Through SIRT3/PARP-1 Pathway , 2021, Frontiers in Pharmacology.

[24]  A. Lombardi,et al.  Heart failure in diabetes. , 2021, Metabolism: clinical and experimental.

[25]  T. Lüscher,et al.  Inflammation in Metabolic Cardiomyopathy , 2021, Frontiers in Cardiovascular Medicine.

[26]  C. Lang,et al.  Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention , 2021, Frontiers in Cardiovascular Medicine.

[27]  E. Ferrannini,et al.  Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence , 2021, Cardiovascular Diabetology.

[28]  J. Corbett,et al.  The Role of Thioredoxin/Peroxiredoxin in the β-Cell Defense Against Oxidative Damage , 2021, Frontiers in Endocrinology.

[29]  M. Michal,et al.  Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population , 2021, Journal of clinical medicine.

[30]  Tongzhi Wu,et al.  Lactate and Myocardiac Energy Metabolism , 2021, Frontiers in Physiology.

[31]  M. Brans,et al.  Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models , 2021, Frontiers in Pharmacology.

[32]  James D. Johnson On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes , 2021, Diabetologia.

[33]  Ling-Qing Yuan,et al.  Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization? , 2021, Frontiers in Cell and Developmental Biology.

[34]  G. Booz,et al.  Atrial Natriuretic Peptide31–67: A Novel Therapeutic Factor for Cardiovascular Diseases , 2021, Frontiers in Physiology.

[35]  A. Pfeiffer,et al.  The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update , 2021, Diabetes, obesity & metabolism.

[36]  E. Gozal,et al.  Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2‐knockout mice , 2021, Journal of cellular and molecular medicine.

[37]  R. Tian,et al.  Cardiac Energy Metabolism in Heart Failure , 2021, Circulation research.

[38]  P. Little,et al.  GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential , 2021, International journal of biological sciences.

[39]  C. Ferran,et al.  A20/TNFAIP3 Increases ENOS Expression in an ERK5/KLF2-Dependent Manner to Support Endothelial Cell Health in the Face of Inflammation , 2021, Frontiers in Cardiovascular Medicine.

[40]  Jun Ren,et al.  Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications , 2021, Physiological reviews.

[41]  S. Menini,et al.  Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future , 2021, Antioxidants.

[42]  S. Khaliq,et al.  Dysregulation of circulating miRNAs promotes the pathogenesis of diabetes-induced cardiomyopathy , 2021, PloS one.

[43]  E. Abel,et al.  Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. , 2021, Free Radical Biology & Medicine.

[44]  Z. Giricz,et al.  Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases. , 2021, Free radical biology & medicine.

[45]  Chiadi E. Ndumele,et al.  Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2021, Circulation.

[46]  Xiao-hong Tang,et al.  High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[47]  Arturo Santos,et al.  Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge , 2021, Cells.

[48]  M. Banach,et al.  Effects of statins on myocarditis: A review of underlying molecular mechanisms. , 2021, Progress in cardiovascular diseases.

[49]  M. Bin-Jumah,et al.  Quercetin prevents myocardial infarction adverse remodeling in rats by attenuating TGF-β1/Smad3 signaling: Different mechanisms of action , 2021, Saudi journal of biological sciences.

[50]  W. Ding,et al.  Nlrp3 Deficiency Alleviates Angiotensin II-Induced Cardiomyopathy by Inhibiting Mitochondrial Dysfunction , 2021, Oxidative medicine and cellular longevity.

[51]  Manisha Pandey,et al.  Molecular and Biochemical Pathways of Catalpol in Alleviating Diabetes Mellitus and Its Complications , 2021, Biomolecules.

[52]  V. Demarco,et al.  Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness , 2021, Cardiovascular Diabetology.

[53]  C. Cheung,et al.  Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy , 2021, Cardiovascular Diabetology.

[54]  E. Brady,et al.  Sex and ethnic differences in the cardiovascular complications of type 2 diabetes , 2021, Therapeutic advances in endocrinology and metabolism.

[55]  Murugesan V. S. Rajaram,et al.  Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair , 2020, Cells.

[56]  N. Nair Epidemiology and pathogenesis of heart failure with preserved ejection fraction. , 2020, Reviews in cardiovascular medicine.

[57]  E. Fontaine,et al.  Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes , 2020, Diabetes, obesity & metabolism.

[58]  J. Aran,et al.  Reactive Oxygen Species: Drivers of Physiological and Pathological Processes , 2020, Journal of inflammation research.

[59]  V. Fuster,et al.  The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action. , 2020, Journal of the American College of Cardiology.

[60]  A. Allam,et al.  Edaravone and Acetovanillone Upregulate Nrf2 and PI3K/Akt/mTOR Signaling and Prevent Cyclophosphamide Cardiotoxicity in Rats , 2020, Drug design, development and therapy.

[61]  P. Ponikowski,et al.  Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status , 2020, Circulation.

[62]  D. Moller,et al.  Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action , 2020, bioRxiv.

[63]  N. Chattipakorn,et al.  Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches , 2020, Journal of translational medicine.

[64]  M. Syamsunarno,et al.  DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism , 2020, Heart and Vessels.

[65]  F. Ferdousi,et al.  Effects of Isorhamnetin in Human Amniotic Epithelial Stem Cells in vitro and Its Cardioprotective Effects in vivo , 2020, Frontiers in Cell and Developmental Biology.

[66]  Yulan Zhang,et al.  Endothelial Dysfunction in Diabetic Retinopathy , 2020, Frontiers in Endocrinology.

[67]  César Martín,et al.  Pathophysiology of Type 2 Diabetes Mellitus , 2020, International journal of molecular sciences.

[68]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[69]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[70]  J. Fruchart,et al.  Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease? , 2020, Current Atherosclerosis Reports.

[71]  M. Sharifi-Rad,et al.  Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases , 2020, Frontiers in Physiology.

[72]  A. Zorzano,et al.  Neuregulin, an Effector on Mitochondria Metabolism That Preserves Insulin Sensitivity , 2020, Frontiers in Physiology.

[73]  Xuan Chen,et al.  Inhibition of miR-223 attenuates the NLRP3 inflammasome activation, fibrosis, and apoptosis in diabetic cardiomyopathy. , 2020, Life sciences.

[74]  R. Ritchie,et al.  Basic Mechanisms of Diabetic Heart Disease. , 2020, Circulation research.

[75]  D. Gruson,et al.  Soluble ST2: a complex and diverse role in several diseases. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[76]  R. Pratley,et al.  GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials , 2020, Frontiers in Endocrinology.

[77]  D. Prakoso,et al.  Enhanced Cardiac Phosphoinositide 3-Kinase (p110α) using Gene Therapy Attenuates Cardiac Remodeling in Type 2 Diabetic Mice. , 2020, American journal of physiology. Heart and circulatory physiology.

[78]  L. Cai,et al.  Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence , 2020, Nature Reviews Cardiology.

[79]  N. Kaludercic,et al.  Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy , 2020, Frontiers in Cardiovascular Medicine.

[80]  Tianhui You,et al.  A Synthetic Curcuminoid Analog, (2E,6E)-2,6-bis(2-(trifluoromethyl)benzylidene)cyclohexanone, Ameliorates Impaired Wound Healing in Streptozotocin-Induced Diabetic Mice by Increasing miR-146a , 2020, Molecules.

[81]  A. Trafford,et al.  The Control of Diastolic Calcium in the Heart , 2020, Circulation research.

[82]  V. Conti,et al.  Cardioprotective Effects of Dietary Phytochemicals on Oxidative Stress in Heart Failure by a Sex-Gender-Oriented Point of View , 2020, Oxidative medicine and cellular longevity.

[83]  M. Treppendahl,et al.  Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk , 2020, Diabetes, obesity & metabolism.

[84]  K. Sliwa,et al.  Acute heart failure , 2008, Nature Reviews Disease Primers.

[85]  J. Salazar,et al.  Neprilysin: A Potential Therapeutic Target of Arterial Hypertension? , 2020, Current cardiology reviews.

[86]  A. Mattiazzi,et al.  Unbalance Between Sarcoplasmic Reticulum Ca2 + Uptake and Release: A First Step Toward Ca2 + Triggered Arrhythmias and Cardiac Damage , 2020, Frontiers in Physiology.

[87]  J. Stamler,et al.  Role of Nitric Oxide Carried by Hemoglobin in Cardiovascular Physiology: Developments on a Three-Gas Respiratory Cycle. , 2020, Circulation research.

[88]  A. Murray,et al.  Altered mitochondrial metabolism in the insulin‐resistant heart , 2019, Acta physiologica.

[89]  G. Iacobellis,et al.  Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk , 2019, International journal of molecular sciences.

[90]  Zuyi Yuan,et al.  Zinc supplementation protects against diabetic endothelial dysfunction via GTP cyclohydrolase 1 restoration. , 2019, Biochemical and biophysical research communications.

[91]  A. M. Leone,et al.  Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction , 2019, Front. Physiol..

[92]  G. D. De Keulenaer,et al.  Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure. , 2019, Circulation. Heart failure.

[93]  H. Grill,et al.  Glucagon-like peptide 1 (GLP-1) , 2019, Molecular metabolism.

[94]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[95]  R. Touyz,et al.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure , 2019, Pharmacological Reviews.

[96]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[97]  A. Arya,et al.  Endoplasmic Reticulum Stress Activates Unfolded Protein Response Signaling and Mediates Inflammation, Obesity, and Cardiac Dysfunction: Therapeutic and Molecular Approach , 2019, Front. Pharmacol..

[98]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[99]  E. Solá,et al.  The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes , 2019, Journal of clinical medicine.

[100]  Akshay S. Desai,et al.  Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. , 2019, Circulation.

[101]  T. Arnould,et al.  Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases , 2019, Cells.

[102]  Jibo Han,et al.  Kaempferol Prevents Against Ang II-induced Cardiac Remodeling Through Attenuating Ang II-induced Inflammation and Oxidative Stress , 2019, Journal of cardiovascular pharmacology.

[103]  A. Lenzi,et al.  Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte , 2019, International journal of molecular sciences.

[104]  V. Fernandes,et al.  Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in young patients with congenital generalized lipodystrophy , 2019, Diabetology & Metabolic Syndrome.

[105]  D. H. Tran,et al.  Glucose Metabolism in Cardiac Hypertrophy and Heart Failure , 2019, Journal of the American Heart Association.

[106]  G. Liang,et al.  Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[107]  P. Deedwania,et al.  Cardiovascular Protection with Anti-hyperglycemic Agents , 2019, American Journal of Cardiovascular Drugs.

[108]  N. Esser,et al.  Neprilysin inhibition: a new therapeutic option for type 2 diabetes? , 2019, Diabetologia.

[109]  M. Volpe,et al.  ARNi: A Novel Approach to Counteract Cardiovascular Diseases , 2019, International journal of molecular sciences.

[110]  Lulu Chen,et al.  Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies , 2019, Cardiovascular Diabetology.

[111]  B. Hocher,et al.  The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury , 2019, Kidney and Blood Pressure Research.

[112]  Z. Cao,et al.  BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine , 2019, International journal of molecular sciences.

[113]  Shanping Wang,et al.  Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress. , 2019, Journal of pharmacological sciences.

[114]  J. Goldberger,et al.  Autonomic Nervous System Dysfunction: JACC Focus Seminar. , 2019, Journal of the American College of Cardiology.

[115]  Maruf M. U. Ali,et al.  Structure and Molecular Mechanism of ER Stress Signaling by the Unfolded Protein Response Signal Activator IRE1 , 2019, Front. Mol. Biosci..

[116]  J. Badimón,et al.  Metabolism of the failing heart and the impact of SGLT2 inhibitors , 2019, Expert opinion on drug metabolism & toxicology.

[117]  N. Wong,et al.  Epidemiology of Diabetes Mellitus and Cardiovascular Disease , 2019, Current Cardiology Reports.

[118]  S. Shukla,et al.  Proteasome biology and therapeutics in cardiac diseases , 2019, Translational research : the journal of laboratory and clinical medicine.

[119]  Matthew J. Crowley,et al.  Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes , 2019, Current Diabetes Reports.

[120]  Angelos Liontos,et al.  SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses , 2019, Postgraduate medicine.

[121]  R. Eckel,et al.  Statin Toxicity: Mechanistic Insights and Clinical Implications , 2019, Circulation research.

[122]  A. Mebazaa,et al.  Adrenomedullin in heart failure: pathophysiology and therapeutic application , 2018, European journal of heart failure.

[123]  Deli Zhang,et al.  Role of Autophagy in Proteostasis: Friend and Foe in Cardiac Diseases , 2018, Cells.

[124]  A. Sposito,et al.  GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data , 2018, Cardiovascular Diabetology.

[125]  P. Newsholme,et al.  Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function , 2018, Front. Endocrinol..

[126]  J. Hecksher-Sørensen,et al.  The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.

[127]  S. Houser,et al.  Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control , 2018, Front. Physiol..

[128]  J. Herance,et al.  The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes , 2018, Scientific Reports.

[129]  Jian Sun,et al.  Cardioprotective effects of the novel curcumin analogue C66 in diabetic mice is dependent on JNK2 inactivation , 2018, Journal of cellular and molecular medicine.

[130]  S. Petak,et al.  Cardiac Autonomic Neuropathy in Diabetes Mellitus. , 2018, Methodist DeBakey cardiovascular journal.

[131]  A. Farcomeni,et al.  Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects , 2018, Acta Diabetologica.

[132]  D. Campbell,et al.  Neprilysin Inhibitors and Bradykinin , 2018, Front. Med..

[133]  Anil Poudel,et al.  Diabetes and Associated Cardiovascular Complications in American Indians/Alaskan Natives: A Review of Risks and Prevention Strategies , 2018, Journal of diabetes research.

[134]  J. Sowers,et al.  Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness , 2018, Hypertension.

[135]  S. Cadenas Mitochondrial uncoupling, ROS generation and cardioprotection. , 2018, Biochimica et biophysica acta. Bioenergetics.

[136]  Claudio Aguayo,et al.  Association between insulin resistance and the development of cardiovascular disease , 2018, Cardiovascular Diabetology.

[137]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[138]  M. George,et al.  Novel approaches in the treatment of diabetic cardiomyopathy. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[139]  T. Einarson,et al.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.

[140]  A. Huqi,et al.  Trimetazidine and Other Metabolic Modifiers. , 2018, European cardiology.

[141]  Sang-Mo Kwon,et al.  Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis , 2018, International journal of molecular sciences.

[142]  N. Ghosh,et al.  Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides , 2018, Cardiovascular Diabetology.

[143]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[144]  G. Liang,et al.  Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress , 2018, Endocrine.

[145]  T. Biering-Sørensen,et al.  Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease , 2018, Scientific Reports.

[146]  M. R. Prajapati,et al.  Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor , 2018, Indian heart journal.

[147]  John R. Petrie,et al.  Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms , 2017, The Canadian journal of cardiology.

[148]  C. Hetz,et al.  The Unfolded Protein Response and Cell Fate Control. , 2017, Molecular cell.

[149]  H. Young,et al.  The SarcoEndoplasmic Reticulum Calcium ATPase. , 2018, Sub-cellular biochemistry.

[150]  J. A. Nogueira-Machado,et al.  Cellular death, reactive oxygen species (ROS) and diabetic complications , 2018, Cell Death & Disease.

[151]  Jian Xiao,et al.  Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts , 2017, Diabetes.

[152]  J. Udell,et al.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials , 2017, Circulation.

[153]  R. Seeley,et al.  The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice , 2017, Molecular metabolism.

[154]  H. Tomita,et al.  Thioredoxin 2 Offers Protection against Mitochondrial Oxidative Stress in H9c2 Cells and against Myocardial Hypertrophy Induced by Hyperglycemia , 2017, International journal of molecular sciences.

[155]  G. Ma,et al.  Erythropoietin Attenuates Cardiac Dysfunction in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Diabetic Cardiomyopathy , 2017, Cardiovascular Drugs and Therapy.

[156]  R. Guo,et al.  Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[157]  B. Staels Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. , 2017, The American journal of cardiology.

[158]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .

[159]  A. Nandy,et al.  Protocatechuic Acid, a Phenolic from Sansevieria roxburghiana Leaves, Suppresses Diabetic Cardiomyopathy via Stimulating Glucose Metabolism, Ameliorating Oxidative Stress, and Inhibiting Inflammation , 2017, Front. Pharmacol..

[160]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.

[161]  S. Bergante,et al.  Effects of Polyphenols on Oxidative Stress-Mediated Injury in Cardiomyocytes , 2017, Nutrients.

[162]  Wang-Soo Lee,et al.  Diabetic cardiomyopathy: where we are and where we are going , 2017, The Korean journal of internal medicine.

[163]  Z. Wang,et al.  Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway , 2017, Molecular and Cellular Biochemistry.

[164]  T. Heise,et al.  Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension , 2017, Clinical pharmacology and therapeutics.

[165]  Qinghua Wang,et al.  Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies , 2017, Front. Physiol..

[166]  W. Cefalu,et al.  An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus , 2016, Current opinion in endocrinology, diabetes, and obesity.

[167]  P. Seferovic,et al.  Heart Failure in Patients with Diabetes Mellitus. , 2016, Cardiac failure review.

[168]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[169]  J. Sowers,et al.  Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease , 2017, Diabetologia.

[170]  Susmita Das,et al.  Sansevieria roxburghiana Schult. & Schult. F. (Family: Asparagaceae) Attenuates Type 2 Diabetes and Its Associated Cardiomyopathy , 2016, PloS one.

[171]  J. Russell,et al.  Diabetes and Cognitive Impairment , 2016, Current Diabetes Reports.

[172]  I. Arisi,et al.  TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice , 2015, Molecular metabolism.

[173]  Z. Kassiri,et al.  Extracellular matrix communication and turnover in cardiac physiology and pathology. , 2015, Comprehensive Physiology.

[174]  V. De Feo,et al.  Abroma augusta L. (Malvaceae) leaf extract attenuates diabetes induced nephropathy and cardiomyopathy via inhibition of oxidative stress and inflammatory response , 2015, Journal of Translational Medicine.

[175]  Iciar Martín-Timón,et al.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? , 2014, World journal of diabetes.

[176]  P. Manning,et al.  Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease , 2014, Cardiovascular Diabetology.

[177]  N. Mochizuki,et al.  Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. , 2013, American journal of physiology. Heart and circulatory physiology.

[178]  J. González-Juanatey,et al.  Coronary artery disease is associated with higher epicardial Retinol‐binding protein 4 (RBP4) and lower glucose transporter (GLUT) 4 levels in epicardial and subcutaneous adipose tissue , 2012, Clinical endocrinology.